“…Reported skin related adverse events from phase 3 trials of secukinumab for psoriasis include oral herpes, urticaria, tinea pedis, oral candidiasis, and impetigo, though case reports of other cutaneous reactions have been reported (Table 1), [4,[6][7][8][9][10][11][12][13][14][15][16][17][18]. The Naranjo score is a tool that can help determine the likelihood that a medication in question is responsible for the adverse reaction, which in this case is three (Table 2), [19].…”